P690 Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study

Abstract

Background: Golimumab (GLM) is a subcutaneous anti-TNF agent for treatment of ulcerative colitis (UC). Most studies that investigated associations between therapeutic efficacy and GLM serum concentrations focused on induction therapy. Our aim was to assess clinical and endoscopic efficacy of GLM after 1 year treatment. Method(s): In this prospective trial, patients with moderate-severe UC (endoscopic Mayo (eMayo) score >=2 received induction treatment with GLM 200 mg SQ (at week (w) 0) and 100 mg (at w2)) followed by maintenance treatment with 50 or 100 mg (every 4w), in patients with a bodyweight of less or more than 80 kg, respectively. Serum GLM concentrations were measured with an enzyme-linked immunoassay (Sanquin Laboratories). The therapeutic effect of GLM was assessed at 8-10 weeks after start and after 1 year of treatment. Endoscopic response was defined as >=1 point reduction in eMayo score and endoscopic remission was defined as eMayo score = 3 points and a SCCAI score of